Trial
NCT02227108
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
MedImmune LLC
Collaborators
—
Condition
B-Cell Pediatric ALL
Intervention
Moxetumomab Pasudotox
Why stopped
The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-06